Figure 1.
Major clinical investigators responsible for early diagnostic and therapeutic advances in myeloproliferative neoplasms. Louis Henri Vaquez was the first to describe polycythemia vera, which was later expanded by William Osler. William Dameshek described pathologic links and coined the term “myeloproliferative disorders.” Philip Fialkow identified myeloproliferative neoplasms as a stem cell disease and Louis Wasserman formed the Polycythemia Vera Study Group, the first dedicated organization to study therapies in myeloproliferative neoplasms.